Investment
Features
FeesSafety
Academy
More
Pluang+

Eli Lilly outperforms Novo Nordisk as obesity drug market heats up, raising growth outlooks.

Company Fundamentals
06 Aug 2026
CNBC
View Source
Neutral
Eli Lilly outperforms Novo Nordisk as obesity drug market heats up, raising growth outlooks.

Eli Lilly and Novo Nordisk both beat Q2 estimates and raised their full-year outlooks, but investors favored Lilly, boosting its shares while punishing Novo. Lilly leads the obesity drug market with a 60.9% U.S. share, driven by strong sales of Mounjaro and Zepbound, and raised its revenue guidance amid sustained demand despite pricing pressures. Novo, holding 38.8% market share, also beat expectations but faced investor concerns over its pipeline and growth prospects, especially after mixed trial results and a weaker-than-expected launch of its Wegovy pill. The diverging investor confidence highlights Lilly as the market momentum leader, while Novo works to regain market share and prove its long-term growth strategy.

More News (LLY)

banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App